Determination of Regulatory Review Period for Purposes of Patent Extension; LUCENTIS

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for LUCENTIS, a human biological product, and is publishing this notice as required by law. The FDA made this determination due to patent extension applications submitted to the Director of Patents and Trademarks, Department of Commerce.